Vanguard Group Inc Apellis Pharmaceuticals, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding APLS
# of Institutions
295Shares Held
132MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$283 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$275 Million17.74% of portfolio
-
Morgan Stanley New York, NY9.75MShares$226 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$208 Million0.03% of portfolio
-
Deep Track Capital, LP Greenwich, CT7MShares$162 Million4.3% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.54B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...